Physician profile
Sherma Peter
NPI 1518127687
$6,880.28
in general payments reported to CMS, 2019-2025
39 companies · $919 in 2025
The $919 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $479 · 2021: $819 · 2022: $1,397 · 2023: $1,614 · 2024: $1,001 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,514 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,514.39 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $908.34 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $732.15 | 2020-2025 | |
| Novo Nordisk INC | $624.89 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $526.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $488.92 | 2019-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Astrazeneca Pharmaceuticals LP | $488.50 | 2020-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $466.05 | 2019-2024 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $334.23 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $300.41 | 2019-2023 | Lifevest |
| Exact Sciences Corporation | $207.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $152.97 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $144.16 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $141.79 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $137.03 | 2021-2025 | Gvoke Hypopen |
| Abbott Laboratories | $134.75 | 2021-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherma Peter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.